Core Viewpoint - EDAP TMS SA has secured a €36 million credit facility from the European Investment Bank to support the global expansion of its Focal One Robotic HIFU platform and accelerate the development of new clinical indications for its technology [1][2][3] Group 1: Credit Facility Details - The credit facility consists of three tranches: Tranche A for €11 million at an interest rate of 8%, Tranche B for €12 million at 7%, and Tranche C for €13 million at 6% [8] - The maturity date for each tranche is set at 5 years from the date of disbursement [8] - EDAP plans to draw the first tranche of €11 million in the fourth quarter of 2025 [2] Group 2: Strategic Importance - The financing will enable EDAP to expand the reach of its Focal One Robotic HIFU technology, addressing the growing global demand for non-invasive treatment options for cancer and benign conditions [3][4] - The collaboration with the EIB highlights EDAP's commitment to innovation in urological and gynecological care through advanced robotic HIFU technologies [4] Group 3: Company Background - EDAP TMS is recognized as a leader in robotic energy-based therapies, developing and distributing minimally invasive medical devices using ultrasound technology [7] - The Focal One platform is positioned as a leading prostate focal therapy, with potential applications extending beyond prostate cancer [7]

Core Insights - EDAP TMS SA will have its largest presence at the 120th American Urological Association (AUA) Annual Meeting, showcasing the Focal One Robotic HIFU platform [1][2] - The meeting will highlight the growing acceptance of robotic HIFU technology in the urology community, with numerous hands-on simulations and live demonstrations planned [2][5] Company Activities - The Focal One Robotic HIFU Masterclass will take place at the Keck School of Medicine of USC on April 24-25, featuring lectures and live procedures [5][6] - Expert-led demonstrations and semi-live procedures will be part of the AUA activities, emphasizing the advanced capabilities of the Focal One technology [5][9] Scientific Presentations - The AUA meeting will include the final results of the FARP study, the first randomized controlled trial comparing ultrasound-based focal ablation to robotic prostatectomy for early-stage prostate cancer [3][6] - A notable increase in scientific presentations on focal therapy and ablation for prostate cancer management is expected, indicating a growing interest in this area [5][9] Notable Presentations - Dr. Ruben Olivares will present the first remote transatlantic Focal One Robotic HIFU procedure, showcasing the technology's remote capabilities [3][6] - The FARP study results will be presented by Eduard Baco, providing level-1 evidence to support the use of focal ablation with Focal One [6]